Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Anthera Pharmaceuticals clinical trials
The registry lists 25 studies whose lead sponsor is Anthera Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 14, 2018.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Anthera Pharmaceuticals.
- Anthera Pharmaceuticals25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic FibrosisCompletedNCT02279498Phase 3
- EASY: Extended Access to Sollpura Over YearsCompletedNCT02823964Phase 4
- SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic FibrosisCompletedNCT02734810Phase 3
- RESULT: Reliable, Emergent Solution Using Liprotamase TreatmentStatus unknownNCT03051490Phase 3
- BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous AdministrationCompletedNCT02062684Phase 2/3
- CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without NephritisTerminatedNCT02514967Phase 3
- CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus ErythematosusCompletedNCT01395745Phase 3
- CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without NephritisWithdrawnNCT02074020Phase 3
- BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel VasculitisWithdrawnNCT01598857Phase 2
- BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA NephropathyWithdrawnNCT02052219Phase 3
- MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITPWithdrawnNCT01609452Phase 2/3
- Open-Label Phase III Long-Term Safety Trial of LiprotamaseCompletedNCT00449904Phase 3
- Phase III ALTU-135 CP Safety TrialTerminatedNCT00500084Phase 3
- Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic InsufficiencyCompletedNCT00449878Phase 3
- Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic InsufficiencyCompletedNCT00095732Phase 2
- IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest SyndromeCompletedNCT00434473Phase 2
- FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary SyndromesCompletedNCT00743925Phase 2
- A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.TerminatedNCT01522196Phase 2
- PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus ErythematosusCompletedNCT01162681Phase 2
- A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321CompletedNCT01305746Phase 2
- VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary SyndromeTerminatedNCT01130246Phase 3
- A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal FunctionTerminatedNCT01359579Phase 1
- Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male SubjectsCompletedNCT01359605Phase 1
- PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery DiseaseCompletedNCT00455546Phase 2
- PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery DiseaseCompletedNCT00525954Phase 2